^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Uplizna (inebilizumab-cdon)
i
Other names: MEDI-551, MEDI 551, 16C4-aFuc, A-fucosylated anti-CD19 antibody, VIB0551, MT-0551, VIB 0551, VIB-0551, MT0551, MT 0551, MEDI551
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen, Jiangsu Hansoh Pharma, Mitsubishi Tanabe
Drug class:
CD19 inhibitor
Related drugs:
17d
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) (clinicaltrials.gov)
P2, N=15, Recruiting, Amgen | Initiation date: Nov 2025 --> Apr 2026
Trial initiation date
|
Uplizna (inebilizumab-cdon)
21d
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Amgen | Trial completion date: Jul 2033 --> Oct 2032
Trial completion date
|
Uplizna (inebilizumab-cdon)
1m
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) (clinicaltrials.gov)
P2, N=15, Recruiting, Amgen | Not yet recruiting --> Recruiting
Enrollment open
|
Uplizna (inebilizumab-cdon)
1m
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD (clinicaltrials.gov)
P2, N=15, Not yet recruiting, Amgen
New P2 trial
|
Uplizna (inebilizumab-cdon)
2ms
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (clinicaltrials.gov)
P2, N=98, Recruiting, Amgen | N=140 --> 98 | Trial completion date: Apr 2028 --> Jun 2029 | Trial primary completion date: Jul 2027 --> Sep 2028
Enrollment change • Trial completion date • Trial primary completion date
|
Blincyto (blinatumomab) • Uplizna (inebilizumab-cdon)
3ms
A Study of MT-0551 in Patients With Systemic Sclerosis (clinicaltrials.gov)
P3, N=80, Active, not recruiting, Mitsubishi Tanabe Pharma Corporation | Trial completion date: Apr 2027 --> Aug 2026
Trial completion date
|
Uplizna (inebilizumab-cdon)
3ms
Inectolizumab With Steroid Optimization in Newly Treated NMOSD (clinicaltrials.gov)
P=N/A, N=25, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University
New trial
|
Uplizna (inebilizumab-cdon) • methylprednisolone sodium succinate
4ms
STARGlu-NMO: Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD (clinicaltrials.gov)
P3, N=170, Not yet recruiting, Tianjin Medical University General Hospital
New P3 trial
|
Uplizna (inebilizumab-cdon)
4ms
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (clinicaltrials.gov)
P2, N=140, Recruiting, Amgen | Trial completion date: Aug 2028 --> Apr 2028 | Trial primary completion date: Nov 2027 --> Jul 2027
Trial completion date • Trial primary completion date
|
Blincyto (blinatumomab) • Uplizna (inebilizumab-cdon)
4ms
N-MOmentum LT: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (clinicaltrials.gov)
P4, N=32, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
Enrollment closed
|
Uplizna (inebilizumab-cdon)
5ms
ExTINGUSH: The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (clinicaltrials.gov)
P2, N=116, Recruiting, University of Utah | Trial completion date: Aug 2026 --> Sep 2028 | Trial primary completion date: Oct 2025 --> Sep 2028
Trial completion date • Trial primary completion date
|
cyclophosphamide • Uplizna (inebilizumab-cdon)
5ms
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (clinicaltrials.gov)
P2, N=140, Recruiting, Amgen | Trial completion date: Mar 2027 --> Aug 2028 | Trial primary completion date: Jul 2026 --> Nov 2027
Trial completion date • Trial primary completion date
|
Blincyto (blinatumomab) • Uplizna (inebilizumab-cdon)
Share via
